Growth Metrics

Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2025)

Historic EBITDA for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to -$80.4 million.

  • Ginkgo Bioworks Holdings' EBITDA fell 4777.0% to -$80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$337.8 million, marking a year-over-year increase of 4787.05%. This contributed to the annual value of -$550.3 million for FY2024, which is 3807.96% up from last year.
  • Latest data reveals that Ginkgo Bioworks Holdings reported EBITDA of -$80.4 million as of Q3 2025, which was down 4777.0% from -$57.8 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' EBITDA's 5-year high stood at -$26.7 million during Q3 2021, with a 5-year trough of -$1.7 billion in Q4 2021.
  • Over the past 5 years, Ginkgo Bioworks Holdings' median EBITDA value was -$168.9 million (recorded in 2024), while the average stood at -$297.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 291448.43% in 2021, then skyrocketed by 9004.0% in 2022.
  • Ginkgo Bioworks Holdings' EBITDA (Quarter) stood at -$1.7 billion in 2021, then surged by 90.04% to -$167.8 million in 2022, then dropped by 23.55% to -$207.3 million in 2023, then skyrocketed by 47.13% to -$109.6 million in 2024, then increased by 26.63% to -$80.4 million in 2025.
  • Its last three reported values are -$80.4 million in Q3 2025, -$57.8 million for Q2 2025, and -$90.0 million during Q1 2025.